Bioprinting Patents: Who Leads, Where the Gaps Are 2026
- Filing has plateaued, not grown. Annual filings peaked at 130 in 2023 and the year-over-year trend from the 2022 midpoint (102) shows no further acceleration — this is a maturing claim space, not an emerging one.
- One record dominates the citation graph. US20160288414A1 carries 186 citations, more than double the next most-cited record, signalling a foundational bioprinter architecture that later filings design around rather than ignore.
- Sterilization and cell-culture apparatus outrank pure 3D-printing claims. A61L (667 records) and C12M (165 records) appear alongside B33Y (551), meaning most viable filings bundle printing method with biological compatibility or bioreactor claims rather than printing mechanics alone.
Filing growth compares 2021 (39 records) with 2024 (107) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 853 records in scope (CR5), not by the ranked leaders only.
What the patent record shows about bioprinting
Bioprinting sits at the intersection of additive manufacturing and tissue engineering, and the patent record reflects that hybrid: filings cluster not just in B33Y (3D printing) but heavily in A61L (sterilising and disinfecting materials) and C12M (bioreactor and enzyme apparatus). A filing that claims only print-head mechanics without addressing cell viability, crosslinking chemistry or sterility is filing into a narrower slice of the space than the dataset suggests is defensible. The search corpus captures 853 patent families published between 2015 and mid-2026, concentrated in the years where bioink formulation and scaffold vascularization moved from academic proof-of-concept to filed claims.
Publication lags filing by roughly eighteen months, so the 2026 figure in any trend chart is necessarily incomplete — treat the most recent one or two years as a floor, not a ceiling, on actual filing activity.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 853-family dataset: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
A decade of filings, now flattening
Annual filings rose from 50 in 2017 to a peak of 130 in 2023, then held near the 2022 level of 102 rather than continuing to climb — consistent with a technology area where the foundational claim territory is largely staked out and later entrants file narrower, more specific improvements.
Claims span printing, sterility and cell culture
A61L (667) and B33Y (551) are the two largest subclasses, followed by C12N (261, microorganisms and genetic engineering), B29C (200, plastics shaping) and C12M (165, bioreactor apparatus). The presence of C09D (coatings and inks, 98) and C08L (polymer compositions, 73) as smaller but non-trivial categories shows bioink formulation chemistry is a distinct, separately claimed layer from the printing hardware itself.
Shares are the percentage of the 853 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Bioprinting and Tissue Fabrication with Eureka
This page is one run against one query. Ask Eureka your own question about bioprinting and tissue fabrication and every answer comes back with the patent numbers behind it.
Try EurekaThe foundational filings behind the citation graph
Preparation and applications of RGD conjugated polysaccharide bioinks for 3D bioprinting of human skin (US20190160203A1)
The filing claims an RGD-conjugated alginate hydrogel, with optional nanocellulose or fibrin, as a bioink for 3D bioprinting of human dermis, together with a coaxial needle method for crosslinking the bioink during extrusion. RGD conjugation is claimed specifically for its role in fibroblast adhesion and Collagen I upregulation, and the combination of bioink chemistry with a coaxial-needle delivery method is claimed as a unit rather than as separate elements.Assignee: BICO GROUP AB · Published 2019-05-30
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20160288414A1 | Bioprinter and methods of using same | 186 |
| 2 | US20130017564A1 | Bioprinting station, assembly comprising such bioprinting station and bioprinting method | 80 |
| 3 | US20090263849A1 | Bioprinting Three-Dimensional Structure Onto Microscale Tissue Analog Devices for Pharmacokinetic Study and O… | 80 |
| 4 | US20170087766A1 | Layerless bioprinting via dynamic optical projection and uses thereof | 78 |
| 5 | US20110136162A1 | Compositions and Methods for Functionalized Patterning of Tissue Engineering Substrates Including Bioprinting… | 78 |
| 6 | WO2011107599A1 | Bioprinting station, assembly comprising such bioprinting station and bioprinting method | 77 |
| 7 | KR1020180125776A | Bio-ink composition for the three-dimensional printing and process for preparing the same | 66 |
| 8 | US20150084232A1 | Poly(ethylene glycol) cross-linking of soft materials to tailor viscoelastic properties for bioprinting | 50 |
| 9 | WO2011038373A2 | Three-dimensional bioprinting of biosynthetic cellulose (BC) implants and scaffolds for tissue engineering | 50 |
| 10 | US20190106673A1 | Bioink compositions and methods of preparing and using the same | 47 |
Citation counts inside a searched corpus favour older records by construction — read this as a map of influence on later filings, not as a ranking of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three signals worth acting on before drafting claims in this space.
One bioprinter architecture patent anchors the field
US20160288414A1 sits more than double the citation count of any other record in the corpus. New apparatus claims that touch print-head or deposition-stage design should be checked against this filing's scope before drafting, since later entrants appear to have built around it rather than through it.
Growth has plateaued since the early-2020s surge
The jump from 50 filings in 2017 to a 2023 peak of 130 reflects the field's move from lab technique to filed IP. That the 2022 midpoint already sat at 102 shows the surge front-loaded rather than continued climbing — a sign that broad method claims are increasingly occupied.
Filing strategy is international by default
With EPO at 159 and India at 124 close behind, most serious filers are pursuing multi-jurisdiction protection via PCT rather than single-country filings. A domestic-only US or EP filing in this space is now the exception rather than the norm among the most active assignees.
Co-filing is limited but concentrated
Only ten co-assignee pairs appear across the whole corpus, and the strongest pair shares eight families together. Collaboration in this field is the exception, and where it happens it tends to be a small number of repeat partnerships rather than broad ecosystem-wide co-development.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bioprinting and tissue fabrication, with the prior art for and against each one.
Who is filing, and where momentum has stalled
Recent-year filing activity by assignee tells a different story from cumulative counts: several previously active filers show zero filings in the latest year, some with a full year-over-year drop.
One assignee still filing at pace
Against a field where most tracked assignees show zero filings in the latest year, one entity continues to add families, making it the clearest signal of ongoing rather than historical investment in this space.
Multiple named assignees have gone quiet
A number of previously active filers, including university and corporate assignees, show no filings in the latest year and in some cases a -100% year-over-year change. This does not necessarily mean exit from the field — it may reflect the publication lag — but it is worth tracking before assuming continued activity.
Partnerships cluster around a few repeat pairs
The strongest co-assignee relationship in the dataset spans eight shared families, well ahead of the next pairs at three to four. Where cross-filing happens in bioprinting, it tends to be a durable bilateral relationship rather than a broad consortium.
| Assignee | Recent year | YoY |
|---|---|---|
| Poietis | 4 | — |
| CELLINK AB | 0 | — |
| CollPlant Ltd. | 0 | — |
| Longeva Biotechnology Co., Ltd. | 0 | -100% |
| Aspect Biosystems | 0 | -100% |
| The Regents of the University of California | 0 | — |
| Sichuan Revotek Co., Ltd. | 0 | — |
| King Abdullah University of Science and Technology (KAUST) | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether you are drafting, freedom-to-operate checking, or scouting partners.
Check freedom-to-operate against the foundational bioprinter claims
Before drafting apparatus claims, review scope on the most-cited records in this corpus, particularly the bioprinter architecture and layerless projection filings that anchor the citation graph.
Explore prior art in EurekaDraft into the under-claimed branches
Vascularization channel geometry and printability rheology standards show thinner filing density than the core bioink and apparatus claims — a narrower, more specific claim here has more room than a broad method claim.
Run a white space search in EurekaTrack assignees that have gone quiet
Several previously active filers show zero filings in the latest year. Confirm whether this reflects the publication lag or an actual shift in strategy before treating their portfolios as static.
Monitor assignee activity in EurekaCommon questions about bioprinting patents
The single most-cited record in this dataset is US20160288414A1, 'Bioprinter and methods of using same,' with 186 citations, well ahead of the next-ranked filings. A cluster of other highly cited records from the late 2000s and early 2010s cover bioprinting stations, dynamic optical projection printing, and functionalized tissue-engineering substrates. These records function as the prior-art baseline that most later apparatus and method claims in the field are drafted around, so any freedom-to-operate review should start there rather than with recent filings.
Filing volume rose steadily from 50 in 2017 to a peak of 130 in 2023, but the 2022 midpoint had already reached 102, indicating the growth curve flattened before the peak year rather than continuing to accelerate afterward. Because publication lags filing by roughly eighteen months, the final one to two years of any trend chart will understate true activity, but the flattening pattern across 2022-2023 predates that lag window and looks like a genuine plateau. This suggests the broadest method and apparatus claims are increasingly occupied, pushing new filings toward narrower improvements.
Sterilising and disinfecting materials (IPC class A61L) appear in 667 of the 853 records, more than additive manufacturing itself (B33Y, 551 records), which shows that most serious filings bundle print method with biocompatibility and sterility claims rather than treating printing mechanics in isolation. Microorganism and genetic engineering claims (C12N, 261) and bioreactor apparatus (C12M, 165) are also substantial. Coatings and inks (C09D) and polymer compositions (C08L) form a smaller but distinct layer covering bioink formulation chemistry specifically.
Relative to the dense core of bioink formulation and printer apparatus claims, sub-areas such as vascularization channel geometry, multi-material coaxial crosslinking, and in-bioreactor perfusion monitoring show thinner filing density. These are technically specific enough to support a defensible narrow claim without immediately colliding with the foundational bioprinter and bioink patents that dominate the citation graph. A first claim in these areas is more likely to succeed if it specifies a concrete structural or process parameter rather than a broad method.
Recent-year filing data shows a small number of assignees still actively filing while several previously prominent names, including corporate and university assignees, recorded zero filings in the latest tracked year, some with a full year-over-year drop to zero. Co-assignee collaboration is also limited to ten pairs across the entire 853-family corpus, with the strongest single partnership at eight shared families. This points to a field where activity is concentrated among a handful of persistent filers rather than broadly distributed, though the publication lag means the most recent year should be read cautiously.
Research Bioprinting and Tissue Fabrication in depth with Eureka
Go past this page: query the whole bioprinting and tissue fabrication corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.